Featured Content

The CenterWatch Monthly Industry Snapshot, July 2017

Saturday, July 1, 2017

Healthcare stakeholders recognize that there is a clear, ethical rationale to support patient engagement in clinical trials. Setting standards that describe how patient engagement is achieved will lead to research findings that are more pertinent to patients’ concerns and dilemmas.1 However, as there are limited comparative analytic studies to recommend a particular method that improves understanding of patients’ concerns1 and enables comparisons of the methods employed, it is unclear how to best engage patients and how to measure the success of engagement.

[Read More]

Revisiting patient diversity in clinical trials… again

Saturday, July 1, 2017

Minority groups have historically been excluded from clinical research, an inequity that has led to well-documented public health problems in which therapies tested primarily in Caucasian patients do not work as well in other ethnic and racial groups. This problem is famously exemplified by Sanofi’s blood thinner Plavix, which was approved in 1997 but slapped with a boxed warning in 2010 after researchers realized up to half of Asian and Pacific Islander populations cannot process the drug.

[Read More]

QuintilesIMS to buy DrugDev

Monday, June 26, 2017

QuintilesIMS has reportedly reached an agreement to buy DrugDev, a technology company that has built one of the industry’s largest global investigator networks and data sharing platforms, the latest in series of significant mergers among CROs during recent months.   

[Read More]

CNS-centric CRO matching service launches

Monday, June 19, 2017

A new matching service has launched for scientists working in the therapeutic area of the central nervous system (CNS) who are ready to move their discoveries from the bench to trials, but have no idea where to turn when it comes to finding and choosing a CRO or lab that knows their therapeutic area well.

[Read More]

Pharmacovigilance in the Russian Federation

Thursday, June 15, 2017

In the Russian Federation, two codes of rules for pharmacovigilance are presently used. The local regulatory body responsible for pharmacovigilance is the Federal Service for Surveillance in Healthcare (RosZdravNadzor) and the Federal State Budgetary Institution named the Centre for Monitoring and Clinical Economic Expertise under the RosZdravNadzor.

[Read More]

Assessing the strategic impact of supply chain management

Thursday, June 15, 2017

The globalization of clinical trials and more complex protocols, which include adaptive designs and those for targeted therapies, have driven the need for new practices and strategies to reduce waste and inefficiencies in the clinical supply logistics area.

[Read More]

Improved perception of the industry

Monday, June 12, 2017

The 2017 Global Pharmaceutical Reptrak study, prepared each year by Boston’s Reputation Institute, showed that the public’s perception of the pharmaceutical industry has improved, earning an industry score of 71.8, up from 68.2 in 2016. Furthermore, about 44% of respondents viewed the industry as having an excellent reputation, a seven point increase since 2016. Similarly, the number of respondents who perceived the industry as weak or poor declined, moving to 26% from 35% in 2016.

[Read More]